Literature DB >> 18471956

Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT.

George A Alexiou1, George Vartholomatos, Spyridon Tsiouris, Athanasios Papadopoulos, Athanasios P Kyritsis, Konstantinos S Polyzoidis, Spyridon Voulgaris, Andreas D Fotopoulos.   

Abstract

OBJECTIVES: Although meningiomas usually have a benign clinical course, atypical and malignant types of this brain tumor are associated with high recurrence rates and poor outcome; thus, DNA ploidy and S-phase -- as determined by DNA flow cytometry -- are useful indicators of their biological behavior. Brain single-photon emission computed tomography (SPECT) has been suggested as a potentially useful modality for the metabolic assessment of various brain tumors. This study evaluated whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake correlates with meningioma proliferative activity, as assessed by flow cytometry analysis. PATIENTS AND METHODS: Ten consecutive patients (3 males, 7 females, mean age 64.6 years) with a diagnosis of a symptomatic intracranial meningioma, planned to undergo surgery, were studied. Brain SPECT by (99m)Tc-TF was performed within a week prior to surgical excision and flow cytometric analysis was performed in the excised tissue. Tumoral radiotracer accumulation was first assessed visually. Semiquantitative image analysis was also performed, by calculating the lesion-to-normal (L/N) uptake ratio.
RESULTS: Benign meningiomas were diagnosed in 8/10 cases, the remaining 2/10 patients had anaplastic lesions. DNA aneuploidy was found in 2 lesions, the remaining tumors were diploid. There was a significant correlation between tracer uptake and the percentage of the cell fraction on S-phase (r=0.733, P=0.05). There was also a positive correlation between tracer uptake and the level of aneuploidy and tumor grade.
CONCLUSION: These results imply that (99m)Tc-TF brain SPECT may have the ability to discriminate benign meningiomas from malignant meningiomas pre-operatively, the tracer uptake being a likely indicator of their proliferative activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471956     DOI: 10.1016/j.clineuro.2008.03.016

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  9 in total

1.  Technetium Tc99m-tetrofosmin brain single-photon emission CT for the diagnosis of malignant meningiomas.

Authors:  G A Alexiou; S Voulgaris; S Tsiouris; A D Fotopoulos; A P Kyritsis; K S Polyzoidis
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-04       Impact factor: 3.825

2.  99mTc-tetrofosmin SPECT for glioma evaluation.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Spyridon Voulgaris; Konstantinos S Polyzoidis; Andreas D Fotopoulos
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

3.  Technetium Tc99m tetrofosmin single-photon emission CT for the assessment of glioma proliferation.

Authors:  G A Alexiou; K S Polyzoidis; S Voulgaris; S Tsiouris; A D Fotopoulos; A P Kyritsis
Journal:  AJNR Am J Neuroradiol       Date:  2008-11       Impact factor: 3.825

4.  99mTc-Tetrofosmin SPECT for the detection of glioma recurrence.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Konstantinos S Polyzoidis; Andreas D Fotopoulos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-20       Impact factor: 9.236

5.  Influence of glioma's multidrug resistance phenotype on (99m)Tc-tetrofosmin uptake.

Authors:  George A Alexiou; Anna Goussia; Athanasios P Kyritsis; Spyridon Tsiouris; Antigoni Ntoulia; Vassiliki Malamou-Mitsi; Spyridon Voulgaris; Andreas D Fotopoulos
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

6.  Characterization of intracranial space-occupying lesions by ⁹⁹(m)Tc-Tetrofosmin SPECT.

Authors:  Andreas D Fotopoulos; Athanasios P Kyritsis; Spyridon Tsiouris; Jihad Al-Boucharali; Athanasios Papadopoulos; Spyridon Voulgaris; George A Alexiou
Journal:  J Neurooncol       Date:  2010-05-23       Impact factor: 4.130

Review 7.  Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Spyridon Voulgaris; Maria I Argyropoulou; Andreas D Fotopoulos
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

Review 8.  Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.

Authors:  Chrissa Sioka; Athanassios P Kyritsis
Journal:  J Neurooncol       Date:  2008-11-21       Impact factor: 4.130

9.  SPECT and PET imaging of meningiomas.

Authors:  Varvara Valotassiou; Anastasia Leondi; George Angelidis; Dimitrios Psimadas; Panagiotis Georgoulias
Journal:  ScientificWorldJournal       Date:  2012-05-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.